OakChart

Mimedx Group Inc

MDXGHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:10 PM ET

3.36-0.01 (-0.30%)
2026-11-11 21:10 CET
Market cap
491.77 USD m
Revenue, TTM
303.73 USD m
Net income, TTM
-19.19 USD m
Free cash flow, TTM
18.98 USD m
EPS diluted, TTM
-0.13
P/E
-
Compare

Price

MDXG against its 20, 50 and 200-day averages
2050200miss
3.004.005.006.003.1M6.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MDXGclose 3.3620-day 3.7650-day 4.31200-day 4.193.3652w low

56.1% under the 52-week high of 7.66 on 11 Nov 2025. 52-week low 3.03 on 29 Apr 2026. Last 15 sessions, 32.0% high to low

Volume 0.58× normal · the line is the 50-bar volume average

Profile

MDXG
52-week range, 7% of the way up
3.037.66

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.

IndexRUT
Employees808
IPOAug 22, 2007
Beta1.19
ATR, 14d0.21
Rel volume0.58
Short float7.84%
Insider own21.58%
Inst own57.50%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap490.31M
Enterprise Value369.52M
Income-19.19M
Sales303.73M
Book/sh1.45
Cash/sh0.83
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees808
IPOAug 22, 2007

Ratios

P/E-
Forward P/E46.67
PEG-
P/S1.61
P/B2.32
P/C4.06
P/FCF25.83
EV/EBITDA-
EV/Sales1.22
Quick Ratio3.84
Current Ratio4.35
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.13
EPS next Y0.07
EPS next Q0.02
EPS this Y-135.94%
EPS next Y162.61%
EPS next 5Y-17.96%
EPS past 3/5Y- -
Sales past 3/5Y16.05% 11.02%
EPS Y/Y TTM-147.20%
Sales Y/Y TTM-22.80%
EPS Q/Q-153.17%
Sales Q/Q-45.23%
EarningsOct 28 AMC
EPS/Sales Surpr.-20100.00% -9.16%

Ownership

Insider Own21.58%
Insider Trans0.00%
Inst Own57.50%
Inst Trans-1.14%
ROA-6.58%
ROE-8.53%
ROIC-9.09%
Gross Margin76.95%
Oper. Margin-8.28%
Profit Margin-6.32%
SMA20-10.66%
SMA50-21.95%
SMA200-19.77%
Trades-

Technical

Shs Outstand145.93M
Shs Float114.44M
Short Float7.84%
Short Ratio6.82
Short Interest8.97M
52W High7.66 -56.14%
52W Low3.03 11.07%
Volatility6.29% 6.43%
ATR (14)0.21
RSI (14)29.23
Beta1.19
Rel Volume0.58
Avg Volume1.31M
Volume665,372

Performance

Perf Week5.00%
Perf Month-28.36%
Perf Quarter-20.00%
Perf Half Y-4.55%
Perf YTD-50.37%
Perf Year-55.44%
Perf 3Y-43.43%
Perf 5Y-58.92%
Perf 10Y-63.91%
Recom1.00
Target Price7.00
Prev Close3.37
Price3.36
Change %-0.30%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
Feb 23, 2026InitiatedCCitizensMkt Outperform$10+197.6%
Jul 02, 2024InitiatedCCantor FitzgeraldOverweight$11+227.4%
Mar 07, 2024InitiatedLLake StreetBuy$12+257.1%
Oct 27, 2023InitiatedCCraig HallumBuy$12+257.1%
Oct 13, 2022InitiatedMMizuhoBuy$7+108.3%
Jul 26, 2021InitiatedNNorthland CapitalOutperform$23+584.5%
Mar 19, 2021InitiatedHH.C. WainwrightBuy$20+495.2%

Peers

Mkt cap
TickerCompanyMkt cap
BSEMBioStem Technologies Inc26.98M
ORGOOrganogenesis Holdings Inc133.05M
VCELVericel Corp2.99B
MDWDMediWound Ltd176.74M
HUMAHumacyte Inc156.04M
SMTISanara MedTech Inc291.64M
RCELAVITA Medical Inc431.35M
CNXUConexeu Sciences Inc72.14M
BVSBioventus Inc934.46M
CLGNCollPlant Biotechnologies Ltd7.62M

Insider trading

3 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Maersk-Moller KimberlyChief Commercial OfficerMar 10 '26Option Exercise4.5042,845192,802357,482Mar 12 05:37 PM
Hulse William Frank IVGeneral Counsel and CAOMar 10 '26Option Exercise4.50136,364613,638624,900Mar 12 05:35 PM
DOUG RICEChief Financial OfficerMar 10 '26Option Exercise4.50243,0001,093,500508,678Mar 12 05:34 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
AVUVAvantis U.S. Small Cap Value ETFAUM: 32.39B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
DFATU.S. Targeted Value Portfolio-ETF Class SharesAUM: 14.47B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-28-0.0600.000-0.06062.2868.565
2026Q22026-07-29-0.100-0.050-0.10064.3663.464
2026Q12026-04-29-0.070-0.026-0.07358.9965.805
2025Q42026-02-250.1000.0880.101118.1106.785
2025Q32025-10-290.1100.0780.112113.73101.914
2025Q22025-07-300.0600.0540.06498.6190.625
2025Q12025-04-300.0500.0540.04788.2186.325
2024Q42025-02-260.0500.0720.05092.9189.425
2024Q32024-10-300.0500.0440.05584.0682.645
2024Q22024-07-310.1200.0750.11887.2189.016
2024Q12024-04-300.0600.0450.06284.7179.326
2023Q42024-02-280.3200.0720.35186.8385.125
2023Q32023-10-300.0600.0460.05781.7176.875
2023Q22023-08-010.000-0.020-0.00581.2674.844
2023Q12023-05-02-0.060-0.087-0.05871.6864.323
2022Q42023-02-28-0.020-0.040-0.01974.3874.544

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2017FY0.3200.3200.557324.5324.5
2020FY-0.615--0.770248.23241.69
2021FY-0.150-0.167-0.149258.62254.89
2022FY-0.330-0.300-0.326267.84267.99
2023FY0.3700.1040.319321.48319.81
2024FY0.2800.2980.285348.88345.37
2025FY0.3200.3200.320418.63407.31
2026FY--0.115--255.87
2027FY-0.072--302.43
2028FY-0.177--373.6
2029FY-0.180--376
2030FY-0.270--423.6

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-10-2950468.5164.9076.84
2026Q4S2026-10-2851175.0471.6077.97
2026Q4S2026-10-1251175.0471.6077.97
2026Q4S2026-10-0951175.0571.6078.00
2026Q4S2026-09-1151076.7771.6080.30
2026Q4S2026-09-0251076.7671.6080.30
2026Q4S2026-08-0840076.6871.6080.30
2026Q4S2026-07-3050076.4671.6080.30
2026Q4S2026-07-2850076.4071.4080.42
2026Q4S2026-07-1450176.4071.4080.42
2026Q4S2026-07-0351476.4071.4080.42
2026Q4S2026-05-2151476.4071.4080.40
2026Q4S2026-05-1461576.3371.4080.40
2026Q4S2026-05-1362481.2571.40106.3

Estimate history

EPS, annual0.557-0.284-0.239-0.77-0.149-0.3260.3190.2850.324-0.132
Period201720182019202020212022202320242025TTM
EPS, quarterly0.0550.050.0470.0640.1120.101-0.073-0.1-0.06
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual321.139359.111299.255248.234258.615267.841321.477348.879418.63303.73
Period201720182019202020212022202320242025TTM
Sales, quarterly84.05792.90788.20598.605113.725118.09558.99164.36262.283
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual109.348109.099110.819110.93111.925113.705146.228146.932148.094145.926
Period201720182019202020212022202320242025MRQ
Shares, quarterly146.963146.932147.608147.925148.076148.094148.931145.724145.926
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue303.73418.63348.88321.48267.84258.62248.23299.25359.11
Cost of Goods Sold Incl. D&A70.0074.4261.7156.4950.5546.6844.1651.6143.30
Gross Profit233.73344.21287.17264.99217.29211.94204.07247.64315.81
Selling, General and Administrative Excl. Other258.87280.32236.56222.69219.84213.13188.98201.85268.41
Research and Development14.4714.7012.0112.3612.4117.0511.3711.1415.77
Other Operating Expense0.000.00-8.705.1812.183.7959.4766.5051.32
Operating Income-25.1463.8959.3137.12-14.73-4.98-44.37-20.71-3.92
Interest Expense1.401.782.546.465.024.987.944.71-
Unusual Expense0.000.001.850.000.000.059.230.450.00
Net Income Before Taxes-22.3866.2657.2930.63-19.75-10.04-61.54-25.59-3.40
Income Taxes-3.1917.6815.30-36.810.210.25-12.26-0.0126.58
Consolidated Net Income-19.1948.5842.0067.44-19.95-10.29-49.28-25.58-29.98
Net Income From Continuing Operations-19.1948.5842.0067.44-19.95-10.29-49.28-25.58-29.98
Net Income-19.1948.5842.4246.59-36.78-16.42-83.33-25.58-29.98
EPS (Recurring)-0.130.320.290.32-0.33-0.15-0.71-0.24-0.28
EPS (Basic, Before Extraordinaries)-0.130.330.290.40-0.33-0.15-0.77-0.24-0.28
EPS (Diluted)-0.130.320.280.32-0.33-0.15-0.77-0.24-0.28
EBITDA-17.3178.7762.3540.54-10.681.19-36.53-12.182.99
Non-Operating Income (Expense)4.174.162.37-0.03-0.00-0.02-0.000.280.53
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.8612.3012.7012.728.5011.1111.568.9811.67
Price To Earnings Ratio--16.44-----4.78
Price To Sales Ratio2.242.424.113.981.172.583.962.710.53
Gross Margin76.9582.2282.3182.4381.1381.9582.2182.7587.94
Operating Margin-8.2815.2617.0011.55-5.50-1.93-17.87-6.92-1.09
Net Margin-6.3211.6012.1614.49-13.73-6.35-33.57-8.55-8.35
Shares Outstanding145.93148.09146.93146.23113.71111.93110.93110.82109.10
Market Capitalization491.77491.771,413.621,020.63316.00677.351,008.29824.92198.75

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue62.2864.3658.99118.09113.7298.6188.2092.91
Cost of Goods Sold Incl. D&A12.8820.2717.6719.1818.8318.7816.6617.10
Gross Profit49.4144.0941.3298.9194.8979.8271.5575.81
Selling, General and Administrative Excl. Other61.1162.5657.3777.8372.7067.4563.3064.61
Research and Development2.802.784.144.763.703.303.333.57
Other Operating Expense0.000.000.000.000.000.000.000.04
Operating Income-11.70-18.47-16.0521.0822.1912.378.2511.15
Interest Expense0.210.390.400.410.420.47-2.53
Unusual Expense0.000.000.000.000.000.000.000.09
Net Income Before Taxes-11.06-17.78-15.3321.8022.8513.018.6111.25
Income Taxes-2.38-2.94-4.476.606.103.391.593.81
Consolidated Net Income-8.68-14.84-10.8615.1916.759.627.027.44
Net Income From Continuing Operations-8.68-14.84-10.8615.1916.759.627.027.44
Net Income-8.68-14.84-10.8615.1916.759.627.027.44
EPS (Recurring)-0.06-0.10-0.070.100.110.060.050.05
EPS (Basic, Before Extraordinaries)-0.06-0.10-0.070.100.110.070.050.05
EPS (Diluted)-0.06-0.10-0.070.100.110.060.050.05
EBITDA-10.24-16.93-14.4324.3027.4815.5311.4511.90
Non-Operating Income (Expense)0.851.071.121.121.081.110.362.72
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.530.71-1.331.953.893.763.363.03
Price To Earnings Ratio-18.8412.1824.8032.3622.6526.7116.44
Price To Sales Ratio2.241.601.512.432.662.513.234.12
Gross Margin79.3368.5070.0583.7683.4480.9581.1281.59
Operating Margin-18.79-28.69-27.2117.8519.5112.559.3512.00
Net Margin-13.94-23.06-18.4112.8614.739.757.968.01
Shares Outstanding145.93145.72148.93148.09148.08147.92147.61146.93
Market Capitalization491.77573.44586.841,002.651,032.75902.461,119.981,413.62

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments166.12104.4282.0065.9587.0895.8169.0745.1227.48
Short Term Receivables75.7155.8353.8743.0841.1045.4732.340.450.66
Inventories25.3423.8121.0213.1811.3910.369.1015.999.47
Other Current Assets10.307.837.3711.987.336.9812.7312.4911.15
Total Current Assets277.47191.89164.26134.20146.90158.62123.2574.0548.75
Net Property, Plant & Equipment9.0611.559.1111.2613.8615.0615.7217.4214.09
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets33.6031.0724.7025.2925.3625.9827.7529.5830.01
Deferred Tax Assets19.6028.3140.780.00---0.0025.54
Other Assets2.931.110.200.681.812.370.441.792.87
Total Assets342.65263.92239.05171.43187.93202.03167.17122.84121.25
Short Term Debt Incl. Current Port. of LT Debt2.822.311.551.441.251.184.920.000.00
Accounts Payable14.537.419.058.457.388.778.7114.868.45
Other Current Liabilities46.9235.8835.4133.6633.7249.2253.6956.6837.36
Total Current Liabilities64.2745.5946.0143.5642.3659.1667.3271.5545.81
Long Term Debt19.7122.5449.0051.0352.0550.6664.830.230.29
Provision for Risks Charges1.301.200.000.000.950.800.000.000.00
Other Liabilities0.831.481.322.330.000.000.621.411.36
Total Liabilities86.1170.8196.3396.9295.35110.61132.7773.1947.46
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.0092.4992.4991.570.000.000.00
Common Equity256.55193.11142.72-17.990.08-0.1534.4049.6673.80
Total Shareholders Equity256.55193.11142.7274.5192.5891.4234.4049.6673.80
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity256.55193.11142.7274.5192.5891.4234.4049.6673.80
Total Liabilities & Stockholders Equity342.65263.92239.05171.43187.93202.03167.17122.84121.25
Book Value Per Share1.731.310.98-0.160.00-0.000.310.460.67
Tangible Book Value Per Share1.511.100.81-0.38-0.23-0.240.060.180.40
Full-Time Employees808837895867811735696753-
Price to Book Ratio2.337.81767.28-16.198,273.97-6,725.9324.422.659.83
Return on Assets16.0216.7032.86-11.10-5.27-26.70-17.64-24.5641.16
Return on Equity21.6125.0162.09-23.88-11.18-78.34-60.87-48.5762.60
Return on Invested Capital17.5819.6730.37-24.05-7.11-34.69-25.78-60.1087.37
Quick Ratio3.923.693.112.783.202.511.700.810.86
Current Ratio4.324.213.573.083.472.681.831.031.06

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-87.9648.5842.0067.44-19.95-10.29-49.28-25.58-29.98
Depreciation7.8314.886.043.434.056.177.848.536.92
Other Funds (Non Cash)86.1124.8111.1212.136.0316.2126.87-2.3114.71
Funds from Operations-1.5996.9871.6345.19-9.8812.10-14.57-19.3617.19
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital22.18-22.98-5.43-18.42-8.01-14.08-15.69-20.0518.60
Income Taxes Payable----0.049.30-10.030.000.00
Cash from Operating Activities20.5974.0066.2026.77-17.89-1.98-30.26-39.4135.80
Capital Expenditures-3.81-3.12-1.72-2.15-2.68-3.47-4.55-2.22-10.03
Net Assets From Acquisitions-5.00-3.76-7.860.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.020.000.000.000.03
Purchase or Sale of Investments2.000.000.000.000.000.000.000.000.00
Purchase of Investments2.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.070.002.720.78
Cash from Investing Activities-6.80-6.89-9.58-2.15-2.66-3.40-4.550.50-9.22
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-14.92-3.12-1.24-8.52-0.54-3.3190.610.11-4.02
Repurchase of Common Pref Stock-14.92-3.12-2.64-9.52-1.19-4.75-2.330.00-7.57
Sale of Common Pref Stock0.000.001.401.000.651.4492.940.113.56
Proceedsfrom Stock Options0.000.000.000.000.000.0092.530.000.00
Issuance or Reduction of Debt, Net-18.25-1.00-32.82-0.05-0.04-0.04-27.6164.22-0.00
Change in Long Term Debt-1.00-1.00-32.82-0.05-0.04-0.04-27.6164.22-0.00
Issuance of Long Term Debt0.000.0048.680.000.000.0056.2766.100.00
Reduction of Long Term Debt-1.00-1.00-81.50-0.05-0.04-0.04-83.87-1.88-0.00
Net Financing Active Other Cash Flow-1.91-1.29-0.140.000.000.00-1.44-1.47-4.91
Other Financing Activities Uses-1.91-1.29-0.140.000.000.00-1.44-1.47-4.91
Cash from Financing Activities-35.08-5.41-34.20-8.57-0.58-3.3561.5662.86-8.93
Net Change in Cash-21.2961.7022.4216.05-21.13-8.7326.7423.9517.64
Free Cash Flow18.9872.9764.5224.79-19.41-5.20-34.49-41.1626.38
Preferred Dividends (Cash Flow)-0.000.00----0.000.00
Price to Free Cash Flow35.8213.8922.2351.64----7.17
Deferred Taxes & Investment Tax Credit-8.7112.47-37.800.000.000.000.0025.54

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments120.79135.84159.77166.12142.08118.87
Short Term Receivables37.2741.3046.0375.7178.1969.23
Inventories22.0920.9326.2325.3426.5024.89
Other Current Assets7.087.308.2910.307.327.89
Total Current Assets187.23205.37240.33277.47254.09220.88
Net Property, Plant & Equipment4.714.914.769.069.6710.38
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets30.5631.5332.5833.6030.5931.47
Deferred Tax Assets29.2227.3024.1319.6021.6527.40
Other Assets12.8311.906.892.932.990.99
Total Assets264.55281.00308.68342.65318.99291.11
Short Term Debt Incl. Current Port. of LT Debt0.001.501.502.821.381.25
Accounts Payable11.838.2911.4614.5311.418.50
Other Current Liabilities31.2028.7031.5946.9244.8940.54
Total Current Liabilities43.0338.5044.5564.2757.6850.29
Long Term Debt0.0015.7116.0919.7116.8417.21
Provision for Risks Charges0.000.000.001.300.000.00
Other Liabilities10.4410.795.100.835.526.98
Total Liabilities53.4765.0065.7486.1180.0474.48
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity211.08216.00242.94256.55238.95216.62
Total Shareholders Equity211.08216.00242.94256.55238.95216.62
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity211.08216.00242.94256.55238.95216.62
Total Liabilities & Stockholders Equity264.55281.00308.68342.65318.99291.11
Book Value Per Share1.451.481.631.731.611.46
Tangible Book Value Per Share1.241.271.411.511.411.25
Full-Time Employees---808--
Price to Book Ratio2.332.362.284.204.774.45
Return on Assets-6.582.1810.6016.0214.5112.26
Return on Equity-8.532.8813.7721.6119.4416.62
Return on Invested Capital-4.11-6.40-4.195.506.554.11
Quick Ratio3.844.794.813.923.953.90
Current Ratio4.355.335.394.324.414.39

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-77.45-14.84-10.8615.1916.759.62
Depreciation1.461.531.623.225.293.17
Other Funds (Non Cash)73.046.610.226.257.545.54
Funds from Operations-4.87-9.87-13.5626.7135.3318.61
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital8.66-0.1615.44-1.76-6.00-4.20
Cash from Operating Activities3.79-10.031.8824.9629.3314.42
Capital Expenditures-0.19-0.64-0.64-2.33-0.19-0.19
Net Assets From Acquisitions0.000.00-5.000.00-3.06-0.70
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.002.00-2.000.00
Purchase of Investments0.000.000.002.00-2.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.19-0.64-5.64-0.34-5.26-0.89
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.37-12.60-1.90-0.05-0.08-0.53
Repurchase of Common Pref Stock-0.37-12.60-1.90-0.05-0.08-0.53
Sale of Common Pref Stock0.000.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-17.25-0.38-0.38-0.25-0.25-0.25
Change in Long Term Debt0.000.000.00-1.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.00-1.000.000.00
Net Financing Active Other Cash Flow-1.02-0.30-0.31-0.28-0.52-0.32
Other Financing Activities Uses-1.02-0.30-0.31-0.28-0.52-0.32
Cash from Financing Activities-18.65-13.27-2.58-0.58-0.86-1.09
Net Change in Cash-15.05-23.93-6.3524.0423.2112.44
Free Cash Flow3.62-10.631.3124.6729.1414.24
Price to Free Cash Flow35.8212.798.4513.9315.3915.67

Revenue breakdown

Surgical2024: 117.88M 2025: 142.30M
Wound2024: 231.00M 2025: 276.33M
United States2024: 348.88M 2025: 418.63M
Total Surgical & Medical Instruments & Apparatus revenue2024: 348.88M 2025: 418.63M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.84%9.0M114.4M1.32M
2026-10-158.10%9.3M114.3M1.21M
2026-09-308.19%9.4M114.3M1.22M
2026-09-159.41%10.8M114.3M1.27M
2026-08-318.21%9.4M114.3M1.29M
2026-08-147.78%8.9M114.3M1.37M
2026-07-317.34%8.4M115.0M1.46M
2026-07-156.40%7.5M117.5M1.57M
2026-06-306.40%7.5M117.7M1.60M
2026-06-156.56%7.7M117.6M1.52M
2026-05-296.43%7.6M117.9M1.48M
2026-05-156.27%7.3M116.5M1.41M
2026-04-307.21%8.4M116.3M1.27M
2026-04-156.41%7.4M116.0M1.06M
2026-03-316.56%7.7M116.8M1.03M
2026-03-135.29%6.2M116.8M946.88K
2026-02-275.74%6.7M116.8M928.23K
2026-02-136.26%7.3M116.5M897.22K
2026-01-306.12%7.1M116.7M947.83K
2026-01-155.43%6.3M116.7M932.42K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.104.901.850.0001.000.000.897-0.0090.001
call5.000.000.050.011.83919.000.000.117-0.0110.001
call7.500.000.750.003.1030.000.000.081-0.0140.001
put2.500.000.050.001.6240.000.00-0.104-0.0080.001
put5.000.302.301.775.3555.000.00-0.883-0.0100.001
put7.503.404.800.006.9950.000.00-0.919-0.0130.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-28425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-10-288-KCurrent report2026-10-28SEC
2026-10-2810-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-16425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-10-168-KCurrent report2026-10-15SEC
2026-09-04EFFECTEffectiveness filing by commission orderSEC
2026-09-04424B3SEC
2026-08-25S-4Registration statement for securities to be issued in business combination transactionsSEC
2026-08-11425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-08-118-K/A2026-07-29SEC
2026-07-30425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-07-30425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-07-29425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-07-298-KCurrent report2026-07-29SEC
2026-07-29425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-07-2910-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-298-KCurrent report2026-07-29SEC
2026-07-29425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-07-29425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-02SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-168-KCurrent report2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-04-29DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-29ARSAnnual report to security holders. 2025-12-31SEC
2026-04-29DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342025-12-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-1100432.33K1

Institutional holders

Manager% owned
Essex Woodlands Management, Inc.19.34%
BlackRock, Inc.8.16%
Nantahala Capital Management, LLC6.40%
Trigran Investments, Inc.4.82%
STATE STREET CORP3.75%
VANGUARD CAPITAL MANAGEMENT LLC3.48%
PARADIGM CAPITAL MANAGEMENT INC/NY2.73%
GEODE CAPITAL MANAGEMENT, LLC2.16%
GOLDMAN SACHS GROUP INC1.79%
AQR CAPITAL MANAGEMENT LLC1.66%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.50%
iShares Russell 2000 ETF2.13%
State Street(R) SPDR(R) S&P(R) Biotech ETF1.99%
Fidelity Small Cap Index Fund0.90%
VANGUARD EXTENDED MARKET INDEX FUND0.89%
iShares Russell 2000 Value ETF0.75%
Avantis U.S. Small Cap Value ETF0.57%
BlackRock Advantage Small Cap Core Fund0.51%
VANGUARD RUSSELL 2000 INDEX FUND0.48%
Paradigm Micro-Cap Fund0.40%

OakChart. MDXG. Cached 15 minutes.